Traditional therapies primarily rely on RAAS blockers, such as ACE inhibitors or ARBs, which can slow albuminuria progression but offer limited efficacy in late-stage DN and fail to reverse renal fibrosis (Samsu, 2021). The gene discussed is ACE; the disease is liver dysplastic nodule.